National Conference of the Italian Group for the Study of Neuromorphology
Vol. 70 No. s2 (2026): 36th National Conference of the Italian Group for the Study of...

PL02 | MULTIPLE FACETS OF ALPHA-SYNUCLEIN PATHOLOGY

Maria Grazia Spillantini | Department of Clinical Neuroscience, University of Cambridge, UK

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 20 November 2026
0
Views
0
Downloads

Authors

Most neurodegenerative diseases are characterised by the presence of abnormal intracellular protein inclusions. These inclusions were described at the beginning of last century as the defining neuropathological features of diseases, such as Alzheimer’s, Pick’s and Parkinson’s (PD). While in AD and Pick’s diseases the intracellular inclusions are made of tau protein, the filamentous inclusions of PD, known as Lewy bodies and Lewy neurites, are made of the protein alpha-synuclein; the same is true for the Lewy pathology of dementia with Lewy bodies and the glial cytoplasmic inclusions of multiple system atrophy. Alpha-synuclein aggregates can be also found in about 60% of Alzheimer’s cases. Alpha-synuclein is a synaptic protein normally involved in brain in vesicle transport and neurotransmitter release. Why it aggregates in synucleinopathies is not known but its involvement in the pathological process is supported by the finding that mutations in its gene (SNCA) cause familial forms of PD. The movement disorders observed in PD have been associated with the appearance of Lewy bodies, Lewy neurites and with the death of dopaminergic neurones in the substantia nigra and the loss of synapses and dopaminergic terminals in the striatum. However, besides the Lewy bodies in the substantia nigra, smaller alpha-synuclein aggregates are present at synapses in the striatum, where they impair neurotransmitter release contributing to axonal degeneration and to the definition of PD as a “dying back disease”. Recent studies have suggested that in PD alpha-synuclein aggregation begins in the periphery, in particular in the gut and nose, and spreads to the brain, resulting in pre-motor and then motor symptoms. We have generated transgenic mouse models with progressive alpha-synuclein aggregation in dopaminergic neurons that reproduce the dopaminergic deficit and neuronal loss in the substantia nigra observed in PD. We have also produced other transgenic mice where we can observe spreading of alpha-synuclein from gut and nose to brain. These mouse models can be used to understand disease mechanisms and to test new therapies to stop PD development.

Downloads

Download data is not yet available.

Citations

How to Cite



1.
PL02 | MULTIPLE FACETS OF ALPHA-SYNUCLEIN PATHOLOGY: Maria Grazia Spillantini | Department of Clinical Neuroscience, University of Cambridge, UK. Eur J Histochem [Internet]. 2026 Nov. 20 [cited 2026 Nov. 20];70(s2). Available from: https://www.ejh.it/ejh/article/view/4794